首个帕金森氏病（PD）疫苗一期研究取得初步进展

首个帕金森病（PD）疫苗一期研究取得初步进展。该疫苗主要针对α-突触核蛋白(alpha-synuclein)---一种在脑内高表达，并在PD患者中呈聚集趋势的蛋白；通过诱导机体产生α-突触核蛋白抗体，来消除该蛋白的毒性影响。

希望成功!

The first vaccine being developed for Parkinson's disease (PD) is showing early promise.

A phase 1 pilot trial of subcutaneous injections of PD01A, carried out at a single center in Vienna, Austria, shows that the vaccine was well tolerated and safe, that it induced an immune response, and that the immune response appeared to be improving function.
......

The vaccine targets alpha-synuclein, a protein that is highly expressed in the brain and that tends to aggregate in patients with PD. It is thought that this process either interferes with normal alpha-synuclein function or is itself toxic to cells. PD01A is designed to stimulate the body to produce antibodies that bind to and clear excess alpha-synuclein.


At the press conference in New York:
left to right: Dr. Frank Mattner, Dr. Todd Sherer,
Dr. Walter Schmidt, Dr. Achim Schneeberger.


来源: http://www.medscape.com/viewarticle/829270

所有跟帖： 

• 希望成功！这个病不知道会不会遗传？ -yhr- ♀ (0 bytes) () 08/21/2014 postreply 19:38:46